Background: To determine EARL-compliant prognostic SUV thresholds in a mature cohort of patients with locally advanced NSCLC, and to demonstrate how detrimental it is to use a threshold determined on an older-generation PET system with a newer PET/CT machine, and vice versa, or to use such a threshold with non-harmonized multicentre pooled data.
Materials And Methods: This was a single-centre retrospective study including 139 consecutive stage IIIA-IIIB patients. PET data were acquired as per the EANM guidelines and reconstructed with unfiltered point spread function (PSF) reconstruction. Subsequently, a 6.3 mm Gaussian filter was applied using the EQ.PET (Siemens Healthineers) methodology to meet the EANM/EARL harmonizing standards (PSF). A multicentre study including non-EARL-compliant systems was simulated by randomly creating four groups of patients whose images were reconstructed with unfiltered PSF and PSF with Gaussian post-filtering of 3, 5, and 10 mm. Identification of optimal SUV thresholds was based on a two-fold cross-validation process that partitioned the overall sample into learning and validation subsamples. Proportional Cox hazards models were used to estimate age-adjusted and multivariable-adjusted hazard ratios (HRs) and their 95% confidence intervals. Kaplan-Meier curves were compared using the log rank test.
Results: Median follow-up was 28 months (1-104 months). For the whole population, the estimated overall survival rate at 36 months was 0.39 [0.31-0.47]. The optimal SUV cutoff value was 25.43 (95% CI: 23.41-26.31) and 8.47 (95% CI: 7.23-9.31) for the PSF and for the EARL-compliant dataset respectively. These SUV cutoff values were both significantly and independently associated with lung cancer mortality; HRs were 1.73 (1.05-2.84) and 1.92 (1.16-3.19) for the PSF and the EARL-compliant dataset respectively. When (i) applying the optimal PSF SUV cutoff on an EARL-compliant dataset and the optimal EARL SUV cutoff on a PSF dataset or (ii) applying the optimal EARL compliant SUV cutoff to a simulated multicentre dataset, the tumour SUV was no longer significantly associated with lung cancer mortality.
Conclusion: The present study provides the PET community with an EARL-compliant SUV as an independent prognosticator for advanced NSCLC that should be confirmed in a larger cohort, ideally at other EARL accredited centres, and highlights the need to harmonize PET quantitative metrics when using them for risk stratification of patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00259-018-4151-8 | DOI Listing |
Objective: To investigate the prognostic value of baseline European Association of Nuclear Medicine Research Ltd. (EARL) standardized [F]fluorodeoxyglucose positron emission tomography-computed tomography ([F]FDG PET-CT) quantitative values for survival and to evaluate cutoff values identified in other studies.
Materials And Methods: Pediatric and adolescent patients with high-grade osteosarcoma were included.
Pathol Oncol Res
January 2025
Department of Nuclear Medicine, Prof. Dr. Cemil Taşcıoğlu City Hospital, University of Health Sciences, Istanbul, Türkiye.
Background And Objectives: This study aims to evaluate the correlation between Tumor-Infiltrating Lymphocyte (TIL) levels and Fluorine-18 fluorodeoxyglucose (F-FDG) metabolic parameters, including spleen and bone marrow FDG uptake and tumor heterogeneity in non-luminal breast cancers (NLBC), and to elucidate their association with survival outcomes.
Methods: We retrospectively analyzed data from 100 females with stage 2-4 NLBC who underwent pretreatment F-FDG Positron emission tomography-computed tomography (PET/CT). TIL was scored based on Hematoxylin-Eosin-stained specimens and F-FDG PET metabolic parameters, including maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), liver, spleen, and bone marrow FDG uptake were calculated.
Otol Neurotol
January 2025
Department of Otolaryngology-Head and Neck Surgery.
Objective: This study aims to identify 18F-FDG-PET imaging features for improving treatment response evaluation in patients with necrotizing otitis externa (NOE), aiding in the difficult differentiation between sterile inflammation and active infection.
Study Design: Retrospective cohort study.
Setting: Tertiary hospital.
Mol Diagn Ther
January 2025
Thoracic Surgery and Lung Transplantation, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, 20122, Milan, Italy.
Objectives: To investigate whether 18F-fluorodeoxyglucose positron emission tomography-computed tomography ([F]F-FDG PET/CT) metabolic parameters were associated with histology and to assess their prognostic role in patients with thymic lesions.
Patients And Methods: In total, 116 patients (49/67 M/F; mean age 59.5 years) who underwent preoperative [F]F-FDG PET/CT and thymectomy from 2012 to 2022 were retrospectively analyzed.
Asia Ocean J Nucl Med Biol
January 2025
Nuclear Medicine Unit, National Cancer Institute (NCI), Cairo University, Cairo, Egypt.
Objectives: to investigate the capability of F-fluorodeoxyglucose positron emission tomography/computed tomography ([F]-FDG PET/CT) derived volumetric parameters to predict human epidermal growth factor receptor 2 (HER2) status in breast cancer patients.
Methods: retrospective study enrolled 47 female patients with breast cancer. All patients had pretreatment [F]-FDG PET/CT.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!